Sugi Predict

Sugi Predict / Compounds / SCHEMBL20305795

SCHEMBL20305795

SCHEMBL20305795

COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCOCCOCCOCCOCCOCC(=O)O

nearest known ligand 0.74

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ EGFR P00533 18/20 0.74
▸ ERBB2 P04626 7/20 0.73
▸ HDAC3 O15379 7/20 0.73
▸ HDAC4 P56524 7/20 0.73
▸ HDAC1 Q13547 7/20 0.73
▸ HDAC7 Q8WUI4 7/20 0.73
▸ HDAC2 Q92769 7/20 0.73
▸ HDAC10 Q969S8 7/20 0.73
▸ HDAC11 Q96DB2 7/20 0.73
▸ HDAC8 Q9BY41 7/20 0.73
▸ HDAC6 Q9UBN7 7/20 0.73
▸ HDAC9 Q9UKV0 7/20 0.73
▸ HDAC5 Q9UQL6 7/20 0.73
▸ KDR P35968 2/20 0.71
▸ AURKA O14965 1/20 0.71
▸ INSR P06213 1/20 0.71
▸ FBP1 P09467 1/20 0.71
▸ PDGFRB P09619 1/20 0.71
▸ FLT4 P35916 1/20 0.71
▸ CLK1 P49759 1/20 0.71

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15217637 0.91 EGFR (0.79) EGFRERBB2HDAC3HDAC4HDAC1
SCHEMBL20305537 0.90 EGFR (0.70) EGFRERBB2HDAC3HDAC4HDAC1
SCHEMBL16295327 0.88 EGFR (0.78) EGFRERBB2KDRAURKAINSR
SCHEMBL13497930 0.88 EGFR (0.79) EGFRERBB2KDRAURKAINSR
SCHEMBL20325421 0.88 KDR (0.72) EGFRHDAC3HDAC4HDAC1HDAC7
SCHEMBL18402669 0.87 EGFR (0.89) EGFRERBB2KDRAURKAINSR
SCHEMBL17327991 0.87 EGFR (0.78) EGFRERBB2KDRAURKAINSR
SCHEMBL17327980 0.86 EGFR (0.70) EGFRERBB2HDAC3HDAC4HDAC1
SCHEMBL15217643 0.86 EGFR (0.79) EGFRERBB2HDAC3HDAC4HDAC1
SCHEMBL15217638 0.86 EGFR (0.79) EGFRERBB2HDAC3HDAC4HDAC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240382599-A1 EGFR PROTEOLYSIS TARGETING CHIMERIC MOLECULES AND ASSOCIATED METHODS OF USE ARVINAS OPERATIONS, INC. 2024-11-21 — — US disclosed
US-20210220475-A1 EGFR PROTEOLYSIS TARGETING CHIMERIC MOLECULES AND ASSOCIATED METHODS OF USE NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2021-07-22 — — US disclosed
US-20210220475-A1 EGFR PROTEOLYSIS TARGETING CHIMERIC MOLECULES AND ASSOCIATED METHODS OF USE NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2021-07-22 — — US disclosed
US-10994015-B2 EGFR proteolysis targeting chimeric molecules and associated methods of use ARVINAS OPERATIONS, INC. (US) 2021-05-04 — — US disclosed
US-10994015-B2 EGFR proteolysis targeting chimeric molecules and associated methods of use ARVINAS OPERATIONS, INC. (US) 2021-05-04 — — US disclosed
CN-110753693-A EGFR proteolytic targeting chimeric molecules and related methods of use 阿尔维纳斯运营股份有限公司 2020-02-04 — — CN disclosed
EP-3559002-A1 EGFR PROTEOLYSIS TARGETING CHIMERIC MOLECULES AND ASSOCIATED METHODS OF USE Arvinas Operations, Inc. (US) 2019-10-30 — — EP disclosed
WO-2018119441-A9 EGFR PROTEOLYSIS TARGETING CHIMERIC MOLECULES AND ASSOCIATED METHODS OF USE ARVINAS OPERATIONS, INC. (US) 2019-10-10 — — WO disclosed
WO-2018119441-A9 EGFR PROTEOLYSIS TARGETING CHIMERIC MOLECULES AND ASSOCIATED METHODS OF USE ARVINAS OPERATIONS, INC. (US) 2019-10-10 — — WO disclosed
US-20180193470-A1 EGFR PROTEOLYSIS TARGETING CHIMERIC MOLECULES AND ASSOCIATED METHODS OF USE ARVINAS OPERATIONS, INC. 2018-07-12 — — US disclosed
US-20180193470-A1 EGFR PROTEOLYSIS TARGETING CHIMERIC MOLECULES AND ASSOCIATED METHODS OF USE ARVINAS OPERATIONS, INC. 2018-07-12 — — US disclosed
US-20180193470-A1 EGFR PROTEOLYSIS TARGETING CHIMERIC MOLECULES AND ASSOCIATED METHODS OF USE ARVINAS OPERATIONS, INC. 2018-07-12 — — US disclosed
WO-2018119441-A1 EGFR PROTEOLYSIS TARGETING CHIMERIC MOLECULES AND ASSOCIATED METHODS OF USE Arvinas, Inc. (US) 2018-06-28 — — WO disclosed
WO-2018119441-A1 EGFR PROTEOLYSIS TARGETING CHIMERIC MOLECULES AND ASSOCIATED METHODS OF USE Arvinas, Inc. (US) 2018-06-28 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240382599-A1 EGFR PROTEOLYSIS TARGETING CHIMERIC MOLECULES AND ASSOCIATED METHODS OF USE TBK1, EGFR, CBL EGFR 2/4885ERBB2 6/4885HDAC3 2798/4885
US-10994015-B2 EGFR proteolysis targeting chimeric molecules and associated methods of use EGFR, ERBB2, ERBB3 EGFR 1/4885ERBB2 2/4885HDAC3 3241/4885
US-20180193470-A1 EGFR PROTEOLYSIS TARGETING CHIMERIC MOLECULES AND ASSOCIATED METHODS OF USE EGFR, ERBB2, ERBB3 EGFR 1/4885ERBB2 2/4885HDAC3 3241/4885
US-20210220475-A1 EGFR PROTEOLYSIS TARGETING CHIMERIC MOLECULES AND ASSOCIATED METHODS OF USE TBK1, EGFR, CBL EGFR 2/4885ERBB2 6/4885HDAC3 2798/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.